2sev­en­ty bio stock drops 24% as com­pe­ti­tion catch­es up with BMS-part­nered mul­ti­ple myelo­ma drug

Com­pet­i­tive pres­sure and a pause in man­u­fac­tur­ing due to rou­tine main­te­nance have pushed US sales of Abec­ma (ide­cab­ta­gene vi­cleu­cel), Bris­tol My­ers Squibb and 2sev­en­ty bio’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER